Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 4/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10269895 | 0.85 | TAAR1 (0.43) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL258030 | 0.83 | TAAR1 (0.42) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL10269575 | 0.82 | LIPG (0.45) | TAAR1ESR2CYP11B2TNKS2PGR | |
| SCHEMBL7860065 | 0.78 | ALDH1A1 (0.41) | CA9PDE3A | |
| SCHEMBL10269560 | 0.75 | ESR2 (0.38) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL19665085 | 0.74 | TAAR1 (0.59) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL31147883 | 0.74 | TAAR1 (0.59) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL30068301 | 0.74 | TAAR1 (0.59) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL20898196 | 0.73 | TAAR1 (0.53) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL31067161 | 0.73 | TAAR1 (0.53) | TAAR1ESR2CYP11B2CYP17A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180244700-A1 | METHODS OF TREATING A FATTY ACID AMIDE HYDROLASE-MEDIATED CONDITION | INFINITY PHARMACEUTICALS, INC. | 2018-08-30 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-9034849-B2 | Fatty acid amide hydrolase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034849-B2 | Fatty acid amide hydrolase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034849-B2 | Fatty acid amide hydrolase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2531511-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | Infinity Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| WO-2011097233-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011097233-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, FASN | TAAR1 2103/4885ESR2 3039/4885CYP11B2 3327/4885 |
| US-20180244700-A1 | METHODS OF TREATING A FATTY ACID AMIDE HYDROLASE-MEDIATED CONDITION | FAAH, FAAH2, FASN | TAAR1 2133/4885ESR2 2277/4885CYP11B2 2852/4885 |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, FASN | TAAR1 2103/4885ESR2 3039/4885CYP11B2 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.